In Vivo Models for Drug Discovery

In vivo pharmacology is essential to evaluate the complex physiological effects of a drug in living organism. WuXi Biology provides in vivo pharmacology studies to evaluate the efficacy, safety and early toxicity of small molecules & biologics. WuXi Biology’s broad expertise and years of preclinical pharmacology experience makes us the ideal partner to conduct your in vivo experiments in all disease areas.

+80 models covering:

Preclinical Integrated Services

in vitro biology, PK-PD and toxicology studies to provide datasets and evidence for IND-enabling

Our scientists provide drug discovery services and tailored solutions to advance your drug candidate selection in multiple disease areas. Through comprehensive discovery and technology platforms, peer-recognized scientific leadership and expertise in oncology, immunology, infectious disease, neurosciences, fibrosis, cardiovascular and metabolic disease, our teams  work collaboratively to rapidly advance programs from target through to preclinical selection and beyond.

Therapeutic areas include:

Neurosciences

neurosciences and animal models for CNS neurodegenerative diseases; Parkinson's, Alzheimer's, dementia

Autoimmune and Inflammatory diseases

in vivo - autoimmune and inflammatory models for arthritis and pain, IBS, IBD, colitits

Oncology & Immuno-oncology

in vivo - Oncology & Immuno-oncology; CDX, PDX, syngeneic xenograft models, PBMC

Cardiovascular & Metabolic diseases

in vivo - Cardiovascular and Metabolic diseases, stroke, obesity, Nephropathy, diabetes, thrombosis

Liver diseases

in vivo - liver disease models of fibrosis, NASH, NAFLD, HCC, hepato-cellular carcinoma, steatosis

Infectious diseases

in vivo - infectious disease models and virology antiviral platform, COVID, RSV, HBV, HCV, influenza

Respiratory diseases

respiratory diseases, idiopathic pulmonary fibrosis, COPD, asthma, fibrosis